Orion OYJ (OTCMKTS:ORINY) Trading Up 2% - Time to Buy?

Key Points

• Orion OYJ shares rose by 2% during trading, reaching a last traded price of $38.95, with trading volume increasing by 32% from the average.
• The company reported a net margin of 22.61% and a return on equity of 38.68%, with quarterly earnings of $0.33 EPS and revenue of $472.57 million.
• Orion OYJ operates in the pharmaceutical sector, providing various prescription drugs and self-care products for multiple health conditions, including cancer and Parkinson’s disease.

Shares of Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) shot up 2% on Tuesday . The company traded as high as $38.95 and last traded at $38.95. 322 shares were traded during mid-day trading, an increase of 32% from the average session volume of 244 shares. The stock had previously closed at $38.18.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered Orion OYJ from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 8th. Two research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company currently has an average rating of "Hold".

Orion OYJ Stock Performance

The stock has a market cap of $10.99 billion, a PE ratio of 26.50 and a beta of 0.11. The company has a quick ratio of 1.05, a current ratio of 1.86 and a debt-to-equity ratio of 0.15. The firm has a 50 day moving average price of $39.47 and a 200 day moving average price of $34.40.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last announced its quarterly earnings results on Friday, July 18th. The company reported $0.33 EPS for the quarter. The firm had revenue of $472.57 million for the quarter. Orion OYJ had a return on equity of 38.68% and a net margin of 22.61%. As a group, research analysts forecast that Orion OYJ Unsponsored ADR will post 1.18 earnings per share for the current year.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.